Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Goodwin Lawyers Provide Updates on Biosimilar Litigation (<i>The Center for Biosimilars</i>)

main

12_27 FEATURE Goodwin Lawyers Provide Updates

FEATURE: Goodwin Lawyers Provide Updates on Biosimilar Litigation <i>(The Center for Biosimilars)</i>

Goodwin Lawyers Provide Updates on Biosimilar Litigation (The Center for Biosimilars)

Related Content

A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond

FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part II: FDA’s Proposed Phaseout Policy – Key Considerations & Open Questions

FDA’s Proposed Rule for Oversight of Laboratory Developed Tests: Part I: Underpinnings of FDA’s Proposed Rule

Modernizing the FDA’s 510(k) Program for Medical Devices: Selection of Predicate Devices and Use of Clinical Data in 510(k) Submissions

A Look Ahead in Life Sciences: What We Are Tracking in Q3 2023 and Beyond

Top IP, FDA, and Compliance Issues for Medtech Companies Transitioning to Data-Enabled Product Solutions

CMS Issues Guidance and Solicits Comment on the 2026 Inflation Reduction Act Part D Negotiation Process

The Long (Un)Winding Road: FDA Maps Out How the End of the Public Health Emergency Will Impact its COVID-19 Policies

Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval

Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma

The American Lawyer Names Rachael Bushey and Jennifer Porter 2024 Dealmakers of the Year

Eidos Therapeutics Signs Exclusive License Agreement with Bayer

BridgeBio Pharma and QED Therapeutics License Skeletal Dysplasias Treatments to Kyowa Kirin for an Upfront Payment of $100 Million Plus Milestones

AVROBIO To Combine With Tectonic Therapeutic In All-Stock Transaction

Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Life Sciences

Life Sciences Regulatory & Compliance

Patent Trial & Appeal Board

Hatch-Waxman, Biologics and Biosimilars Litigation